Pendred Syndrome — the most common syndromic cause of hereditary hearing loss, where SLC26A4 genotype determines whether hearing loss will be progressive and whether thyroid monitoring is needed.
Whole genome sequencing reads the complete SLC26A4 gene — including deep intronic variants recently shown to be pathogenic — providing the molecular diagnosis that distinguishes Pendred syndrome from non-syndromic DFNB4 and guides cochlear implant candidacy.
Pendred Syndrome
Pendred syndrome is an autosomal recessive disorder caused by biallelic pathogenic variants in SLC26A4 (chromosome 7q22.3), encoding pendrin — an anion transporter expressed in the inner ear, thyroid, and kidney. In the inner ear, pendrin is critical for endolymphatic fluid homeostasis; its deficiency causes enlargement of the vestibular aqueduct (EVA) and cochlear anomalies (incomplete partition type II/Mondini malformation). SLC26A4 pathogenic variants are the most common cause of syndromic hereditary hearing loss worldwide and account for approximately 5-10% of all hereditary sensorineural hearing loss.
Hearing loss in Pendred syndrome is typically congenital or early-onset, bilateral, sensorineural, and often progressive — fluctuating losses triggered by minor head trauma or barotrauma are characteristic due to the enlarged vestibular aqueduct. The thyroid component is a euthyroid or subclinical hypothyroid goiter that typically appears in late childhood or adolescence. Many patients never develop clinically apparent goiter, leading to underdiagnosis — they are classified as having 'non-syndromic hearing loss with EVA' (DFNB4) rather than Pendred syndrome. The distinction is molecular: both conditions are caused by SLC26A4 variants.
Cochlear implantation is highly effective for Pendred syndrome/DFNB4 hearing loss, with excellent speech perception outcomes in most patients — often superior to cochlear implant outcomes for other causes of deafness. However, the enlarged vestibular aqueduct anatomy creates surgical considerations (perilymphatic gusher risk during cochleostomy) and requires experienced cochlear implant surgeons. Molecular confirmation of SLC26A4 variants enables proactive thyroid monitoring (annual TSH, thyroid ultrasound), appropriate cochlear implant surgical planning, and counseling about the progressive nature of hearing loss and avoidance of head trauma.
Any child with enlarged vestibular aqueduct (EVA) on temporal bone CT or MRI should have SLC26A4 molecular testing — EVA is present in virtually 100% of biallelic SLC26A4 patients and is the most consistent radiological finding.
SLC26A4 is the most common cause of sensorineural hearing loss with enlarged vestibular aqueduct. Deep intronic SLC26A4 variants are now recognized as pathogenic — and are invisible to exon-only sequencing panels.
SLC26A4 deep intronic variants resolve the 'missing second allele' problem in EVA patients
Many patients with enlarged vestibular aqueduct and hearing loss have only one identifiable SLC26A4 coding variant on standard exon sequencing — the 'missing second allele' problem. Recent research has identified deep intronic SLC26A4 variants that create aberrant splice sites, accounting for a substantial proportion of these previously unsolved cases. These intronic variants are invisible to exon-sequencing panels but are read directly by whole genome sequencing, which evaluates the complete SLC26A4 locus including all introns.
Progressive hearing loss in Pendred syndrome requires different management than stable congenital deafness
Hearing loss in SLC26A4 patients characteristically fluctuates and progresses — episodes of sudden hearing decline can be triggered by head trauma, altitude changes, or even minor physical exertion. Parents of a child with SLC26A4-confirmed hearing loss need specific counseling: avoid contact sports and activities with head trauma risk, seek immediate audiology evaluation after any head injury, and expect that hearing aids may become insufficient over time with eventual need for cochlear implantation. This progressive trajectory is different from stable congenital deafness caused by GJB2 variants and requires different longitudinal management planning.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Pendred Syndrome and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
